Development of this evidence summary

Development of this evidence summary

The evidence summaries: process guide (2017) sets out the process NICE uses to select topics for evidence summaries and details how the summaries are developed, quality assured and approved for publication.

Expert advisers

Professor Robert Coleman, Department of Oncology and Metabolism, University of Sheffield.

Dr John Graham, Consultant Oncologist & Trust Cancer Lead Clinician, Musgrove Park Hospital.

Professor Chris Holcombe, Oncoplastic Breast Surgeon, Royal Liverpool University Hospital.

Dr Karen McAdam, Consultant Medical Oncologist, Cambridge University Hospitals NHS Foundation Trust.

Declarations of interest

Robert Coleman has previously received medical education fees for an unrelated topic from Eisai and Astra Zeneca. His institution currently receives research funding from Amgen and Bayer and has previously received research funding from Novartis. He has published extensively on this topic (including practice guidelines, and advice to commissioners and the Breast Cancer Clinical Reference Group), and contributed to the repurposing of drugs debate through his role as a Board member for Breast Cancer Now.

John Graham is a Clinical Adviser for the National Guideline Alliance, Royal College of Obstetricians & Gynaecologists, and the Vice Chair for NICE Guideline Updates Committee B. He is the principal investigator for various ongoing clinical trials in prostate cancer and breast cancer, 3 of which are funded by Bayer Health Care and 8 of which are run via the National Cancer Research Network, which is not pharmaceutical industry funded. He has received travel expenses from The Conference Forum to attend the Immuno-Oncology 360 Conference.

Chris Holcombe has been paid to chair an Advisory Board for Genomic Health and lecture on behalf of Roche. He has also accepted hospitality to attend a conference provided by the makers of Braxon, an Acellular Dermal Matrix used in breast reconstruction.

Karen McAdam has received a speaker fee from Roche for a meeting on neoadjuvant chemotherapy/anti HER2 therapy for early breast cancer. She previously sat on an advisory board for Novartis and is now an advisory board member for the EISAI First Thoughts meetings.

About this evidence summary

Evidence summaries provide a summary of the best available published evidence for selected new medicines, unlicensed medicines or off-label use of licensed medicines.

The summaries assess the strengths and weaknesses of the best available evidence to inform health professionals and commissioners' decision-making.

This summary is not NICE guidance.

ISBN: 978-1-4731-2598-8